Embolism adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 8,211 adverse event reports that record the MedDRA preferred term Embolism. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 356 reports in the 12 months to June 2026 and 363 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,160 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 356 (under 0.1%) record this term. Reports for female patients were 42.6% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 98 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Embolism name as a suspect product, in order of name
Drug	Class	Reports with this term
Abraxane	Microtubule inhibitor	70
Acetylsalicylic Acid		34
Alteplase		39
Amlodipine	Calcium channel blocker	25
Anakinra	Interleukin-1 receptor antagonist	27
Apixaban	Factor Xa inhibitor	71
Aspirin	Nonsteroidal anti-inflammatory drug	101
Atezolizumab	Programmed death Receptor-1 blocking antibody	142
Avastin	Vascular endothelial growth factor inhibitor	113
Bendamustine		27
Bevacizumab	Vascular endothelial growth factor inhibitor	421
Bextra		91
Bortezomib	Proteasome inhibitor	36
Cabozantinib	Kinase inhibitor	32
Capecitabine	Nucleoside metabolic inhibitor	137
Carboplatin	Platinum-based drug	238
Carfilzomib	Proteasome inhibitor	42
Celebrex	Nonsteroidal anti-inflammatory drug	146
Cetuximab	Epidermal growth factor receptor antagonist	45
Cisplatin	Platinum-based drug	213
Clopidogrel	P2Y12 platelet inhibitor	45
Coumadin		40
Crizotinib	Kinase inhibitor	36
Cyclophosphamide	Alkylating drug	251
Cytarabine	Nucleoside metabolic inhibitor	64
Daratumumab	CD38-directed cytolytic antibody	28
Dexamethasone	Corticosteroid	240
Diovan	Angiotensin 2 receptor blocker	30
Docetaxel	Microtubule inhibitor	88
Doxorubicin	Anthracycline topoisomerase inhibitor	145
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	90
Durvalumab	Programmed death Ligand-1 blocker	35
Eliquis	Factor Xa inhibitor	121
Elspar		47
Enbrel	Tumor necrosis factor blocker	102
Enoxaparin sodium	Low molecular weight heparin	43
Erlotinib	Kinase inhibitor	61
Etoposide	Topoisomerase inhibitor	120
Fluorouracil	Nucleoside metabolic inhibitor	174
Folinic Acid		25
Furosemide	Loop diuretic	25
Gemcitabine	Nucleoside metabolic inhibitor	121
Gemcitabine hydrochloride	Nucleoside metabolic inhibitor	50
Heparin		62
Heparin sodium	Anti-coagulant	30
Herceptin	HER2/neu receptor antagonist	37
Humira		138
Ibrance	Kinase inhibitor	25
Infliximab	Tumor necrosis factor blocker	27
Ipilimumab	CTLA-4-directed blocking antibody	62
Irinotecan		75
Keytruda	Programmed death Receptor-1 blocking antibody	32
Lenalidomide	Thalidomide analog	135
Leucovorin		61
Leucovorin calcium	Folate analog	31
Meropenem	Penem antibacterial	28
Methotrexate	Folate analog metabolic inhibitor	115
Methotrexate sodium	Folate analog metabolic inhibitor	33
Methylprednisolone	Corticosteroid	44
Mycophenolate mofetil	Antimetabolite immunosuppressant	38
Nivolumab	Programmed death Receptor-1 blocking antibody	148
Nplate	Thrombopoietin receptor agonist	50
Nuvaring	Estrogen	36
Opdivo	Programmed death Receptor-1 blocking antibody	28
Orencia	Selective T cell costimulation modulator	30
Oxaliplatin	Platinum-based drug	177
Paclitaxel	Microtubule inhibitor	235
Pegfilgrastim	Leukocyte growth factor	40
Pembrolizumab	Programmed death Receptor-1 blocking antibody	53
Pemetrexed	Folate analog metabolic inhibitor	43
Pradaxa	Direct thrombin inhibitor	177
Prednisolone	Corticosteroid	58
Prednisone	Corticosteroid	177
Remicade	Tumor necrosis factor blocker	26
Revlimid	Thalidomide analog	147
Rinvoq	Janus kinase inhibitor	56
Risperidone	Atypical antipsychotic	31
Rituximab	CD20-directed cytolytic antibody	217
Rivaroxaban	Factor Xa inhibitor	31
Sulfasalazine	Aminosalicylate	29
Tacrolimus	Calcineurin inhibitor immunosuppressant	41
Taxol		26
Temozolomide	Alkylating drug	35
Thalidomide		33
Thalomid		43
Tocilizumab	Interleukin-6 receptor antagonist	53
Trastuzumab	HER2/neu receptor antagonist	66
Velcade	Proteasome inhibitor	47
Vincristine		125
Vioxx		500
Vorinostat	Histone deacetylase inhibitor	27
Warfarin	Vitamin K antagonist	73
Warfarin sodium	Vitamin K antagonist	38
Xarelto	Factor Xa inhibitor	211
Xeljanz	Janus kinase inhibitor	26
Xeloda	Nucleoside metabolic inhibitor	34
Yasmin		34
Yaz		27

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 32 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Embolism name, in order of name
Class	Reports with this term
Alkylating drug	336
Angiotensin 2 receptor blocker	85
Anthracycline topoisomerase inhibitor	240
Atypical antipsychotic	120
Calcineurin inhibitor immunosuppressant	50
CD20-directed cytolytic antibody	246
Corticosteroid	560
CTLA-4-directed blocking antibody	81
Direct thrombin inhibitor	181
Epidermal growth factor receptor antagonist	80
Estrogen	51
Factor Xa inhibitor	448
Folate analog metabolic inhibitor	199
HER2/neu receptor antagonist	123
Interleukin-6 receptor antagonist	56
Janus kinase inhibitor	130
Kinase inhibitor	442
Leukocyte growth factor	62
Low molecular weight heparin	62
Microtubule inhibitor	393
Nonsteroidal anti-inflammatory drug	284
Nucleoside metabolic inhibitor	637
P2Y12 platelet inhibitor	78
Platinum-based drug	628
Programmed death Receptor-1 blocking antibody	419
Proteasome inhibitor	140
Thalidomide analog	309
Thrombopoietin receptor agonist	84
Topoisomerase inhibitor	153
Tumor necrosis factor blocker	189
Vascular endothelial growth factor inhibitor	556
Vitamin K antagonist	111

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Embolism, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Embolism
Age	Reports	Share
Under 2	21	0.3%
2 to 11	52	0.6%
12 to 17	85	1%
18 to 44	692	8.4%
45 to 64	1,693	20.6%
65 to 74	1,187	14.5%
75 and over	858	10.4%
Age not given	3,623	44.1%

Sex of the patient in the reports that record Embolism
Sex	Reports	Share
Female	3,499	42.6%
Male	2,802	34.1%
Unknown or not given	1,910	23.3%

Age and sex are as the report gives them. 40.4% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Embolism: adverse event reports that record this term. https://reportedreactions.com/reaction/embolism/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Embolism mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page